论文部分内容阅读
1969年Baum等经动物实验证明氯苄氨胍有降压作用。其作用比利血平、胍乙啶、α-甲基多巴强,但比肼苯哒嗪、可乐宁稍弱。1973年Nash将此药试用于临床,以12～16mg/日的剂量治疗中等度及重度高血压病患者,认为Gb是一种作用较缓和安全的药物。近十多年来对Gb进行了大量的动物实验及临床研究。Gb的降压作用原理与可乐宁相似,动物实验证明它能透过血脑屏障进入中枢神经系统,兴奋中枢α-受体,减少外周交感冲动而出现降压作用。Gb的降压作用可被相应的α-受体阻断剂所阻断。用脑匀浆作竞争性结合实验证明Gb对α_2
Baum and other animal experiments in 1969 proved that benzmettin had antihypertensive effect. Its role than reserpine, guanethidine, α-methyldopa strong, but less than hydralazine, Clonidine slightly weaker. In 1973, Nash tested the drug for clinical use and treated patients with moderate and severe hypertension at a dose of 12-16mg / day. Gb is considered to be a more potent and safe drug. Nearly a decade of Gb conducted a large number of animal experiments and clinical studies. The principle of antihypertensive action of Gb is similar to that of clonidine. Animal experiments show that it can enter the central nervous system through the blood-brain barrier, excite the central α-receptor, and reduce the peripheral sympathetic impulses. The antihypertensive effects of Gb can be blocked by the corresponding α-receptor blockers. Brain homogenate as a competitive binding experiment to prove Gb to α_2